Company intelligence / Profile preview

Nine Square Therapeutics

San Francisco, California, United Statesninesquaretx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is developing novel Parkin activators for Parkinson's disease and has received a $4.5 million grant from The Michael J. Fox Foundation. They also have programs for ALS in preclinical stage and TRPML1 agonists for neurodegenerative diseases in discovery phase.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

1 asset

parkin activators

Preclinical

Beyond the preview

Go deeper on Nine Square Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nine Square Therapeutics.

Explore the full profile